ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at

Stock News for Gilead Sciences (GILD)
05/28/201521:47:00L'Agence Européenne des Médicaments valide la demande de commercialisation d...
05/28/201520:50:00L’Agenzia europea per i medicinali accoglie la domanda di commercializzazione d...
05/28/201519:00:50Merck Files New Drug Application for Hepatitis Combination
05/28/201511:58:02Gilead's Sustainable Competitive Advantage
05/28/201509:09:02Undervalued Stocks in Biotech Worth Buying
05/28/201508:30:00European Medicines Agency Validates Gilead’s Marketing Application f...
05/27/201518:02:00Gilead inaugure un nouveau laboratoire novateur et annonce un...
05/27/201517:00:00Gilead Sciences to Present at the Bernstein 31st Annual Strategic...
05/27/201516:44:00Gilead cuts ribbon on innovative new laboratory, announces additional...
05/26/201511:33:02Pop! 3 To Buy If Biotech Stocks Burst
05/25/201509:50:13The Best Business Model in Biotech
05/25/201509:45:09The Best Business Model in Biotech
05/25/201509:40:05The Best Business Model in Biotech
05/25/201509:35:04The Best Business Model in Biotech
05/25/201509:30:09The Best Business Model in Biotech
05/25/201509:25:06The Best Business Model in Biotech
05/25/201509:20:07The Best Business Model in Biotech
05/25/201509:15:08The Best Business Model in Biotech
05/25/201509:10:06The Best Business Model in Biotech
05/25/201509:05:04The Best Business Model in Biotech

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations